Related Experiment Videos
MAOI treatment response: multiaxial assessment.
E Giller1, D Bialos, M A Riddle
1Psychiatry Service, West Haven VA Medical Center, CT 06516.
Journal of Affective Disorders
|March 1, 1988
Summary
Isocarboxazid treatment for depression improves symptoms, but work and social functioning may lag. Long-term treatment shows broader functional improvements, indicating complex recovery beyond symptom reduction.
Area of Science:
- Psychiatry
- Clinical Psychology
- Pharmacology
Background:
- Monoamine oxidase inhibitors (MAOIs) like isocarboxazid are used for depression.
- Patient-reported outcomes beyond symptom reduction are crucial for assessing treatment effectiveness.
Purpose of the Study:
- To evaluate the impact of isocarboxazid on multiple functional domains in patients with depression.
- To compare the rate and extent of improvement across symptom, work, family, and social functioning.
Main Methods:
- A study involving patients treated with isocarboxazid for depression.
- Assessment of four outcome areas: symptoms, work, family, and social functioning at 6 and 24 weeks.
Main Results:
- Symptom reduction was the most significant improvement at 6 weeks.
- By 24 weeks, all four functional areas showed further improvement, with work functioning reaching statistical significance.
- Improvement varied across different functional domains over time.
Conclusions:
- Assessing depression treatment efficacy requires evaluating multiple functional areas, not just symptom reduction.
- Different aspects of functioning improve at different rates and to varying degrees during treatment.